Harmony Biosciences Holdings (HRMY) Equity Average (2020 - 2025)
Historic Equity Average for Harmony Biosciences Holdings (HRMY) over the last 6 years, with Q3 2025 value amounting to $804.1 million.
- Harmony Biosciences Holdings' Equity Average rose 4164.36% to $804.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $804.1 million, marking a year-over-year increase of 4164.36%. This contributed to the annual value of $563.1 million for FY2024, which is 2946.75% up from last year.
- According to the latest figures from Q3 2025, Harmony Biosciences Holdings' Equity Average is $804.1 million, which was up 4164.36% from $746.8 million recorded in Q2 2025.
- Harmony Biosciences Holdings' Equity Average's 5-year high stood at $804.1 million during Q3 2025, with a 5-year trough of $102.5 million in Q1 2021.
- For the 5-year period, Harmony Biosciences Holdings' Equity Average averaged around $417.2 million, with its median value being $464.1 million (2023).
- Per our database at Business Quant, Harmony Biosciences Holdings' Equity Average surged by 12058.11% in 2022 and then skyrocketed by 1354.9% in 2024.
- Quarter analysis of 5 years shows Harmony Biosciences Holdings' Equity Average stood at $169.3 million in 2021, then skyrocketed by 120.58% to $373.4 million in 2022, then grew by 27.0% to $474.2 million in 2023, then skyrocketed by 32.44% to $628.0 million in 2024, then increased by 28.05% to $804.1 million in 2025.
- Its Equity Average stands at $804.1 million for Q3 2025, versus $746.8 million for Q2 2025 and $689.8 million for Q1 2025.